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ABSTRACT
Introduction Even though respiratory support is a common 
intervention in paediatric critical care, there is no randomised 
controlled trial (RCT) evidence regarding the effectiveness 
of two commonly used modes of non- invasive respiratory 
support (NRS), continuous positive airway pressure (CPAP) 
and high- flow nasal cannula therapy (HFNC). FIRST- line 
support for assistance in breathing in children is a master 
protocol of two pragmatic non- inferiority RCTs to evaluate 
the clinical and cost- effectiveness of HFNC (compared with 
CPAP) as the first- line mode of support in critically ill children.
Methods and analysis We will recruit participants over 
a 30- month period at 25 UK paediatric critical care units 
(paediatric intensive care units/high- dependency units). 
Patients are eligible if admitted/accepted for admission, 
aged >36 weeks corrected gestational age and <16 years, 
and assessed by the treating clinician to require NRS for an 
acute illness (step- up RCT) or within 72 hours of extubation 
following a period of invasive ventilation (step- down RCT). 
Due to the emergency nature of the treatment, written 
informed consent will be deferred to after randomisation. 
Randomisation will occur 1:1 to CPAP or HFNC, stratified by 
site and age (<12 vs ≥12 months). The primary outcome is 
time to liberation from respiratory support for a continuous 
period of 48 hours. A total sample size of 600 patients in 
each RCT will provide 90% power with a type I error rate of 
2.5% (one sided) to exclude the prespecified non- inferiority 
margin of HR of 0.75. Primary analyses will be undertaken 
separately in each RCT in both the intention- to- treat and 
per- protocol populations.
Ethics and dissemination This master protocol received 
favourable ethical opinion from National Health Service East 
of England—Cambridge South Research Ethics Committee 
(reference: 19/EE/0185) and approval from the Health 
Strengths and limitations of this study
 ► FIRST- line support for assistance in breathing in 
children (FIRST- ABC) is a master protocol of the two 
largest randomised controlled trials (RCTs) to date 
to study the clinical and cost- effectiveness of high- 
flow nasal cannula as the first- line mode of non- 
invasive respiratory support in critically ill children.
 ► The FIRST- ABC master protocol includes two sep-
arate RCTs, one in acutely ill children requiring re-
spiratory support (step- up RCT) and one in children 
requiring respiratory support after extubation from 
invasive ventilation (step- down RCT), to address the 
research question in two distinct but common clin-
ical scenarios.
 ► The design and conduct of FIRST- ABC has been 
informed by a successful pilot RCT that confirmed 
the feasibility of delivering a large pragmatic trial in 
critically ill children.
 ► The choice of the primary outcome, time to libera-
tion from all forms of respiratory support for a con-
tinuous period of at least 48 hours, was informed 
by clinicians as well as through patient and public 
involvement.
 ► Changes to clinical practice during the trial peri-
od, and a resultant shift in equipoise regarding the 
choice of first- line mode of respiratory support in 
critically ill children, may affect the ability to recruit 
successfully to the RCTs.
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Research Authority (reference: 260536). Results will be disseminated via 
publications in peer- reviewed medical journals and presentations at national 
and international conferences.
Trial registration number ISRCTN60048867
INTRODUCTION
Nearly 75% of the 20 000 critically ill children admitted 
annually to UK paediatric intensive care units (PICUs) 
receive some form of respiratory support.1 Increasing 
recognition of the risks of invasive ventilation has prompted 
greater use of non- invasive respiratory support (NRS) 
worldwide.1 2 Two main modes of NRS are used, to support 
acutely ill children with respiratory failure or to provide 
postextubation support after a spell of invasive ventilation.
Continuous positive airway pressure (CPAP) has been 
used by PICUs for over three decades.3–5 Although observa-
tional data suggest that CPAP is effective, there have been 
few randomised controlled trials (RCTs) of CPAP in criti-
cally ill children.5–7 CPAP can be uncomfortable and may 
be associated with complications such as air- leak and nasal 
trauma, often necessitating the use of sedation, close moni-
toring and a high level of nursing input. An alternate mode 
of NRS, high- flow nasal cannula (HFNC), has gained popu-
larity more recently. It appears easy to use and is well toler-
ated.8–11 Between 16% and 35% of PICU admissions receive 
HFNC at some point during their stay.1 12 13 The potential 
benefits of HFNC (improved patient comfort, safety profile 
and ease of nursing care) must be balanced against its 
potential risks (air leak, abdominal distension and noso-
comial infection), and concerns regarding unnecessary 
prolongation of PICU/hospital stay and excess mortality 
from delayed escalation. There are few RCTs comparing 
HFNC with CPAP in the PICU setting. Previous RCTs do 
not include children with a range of ages and diagnoses 
needing either step- up or step- down (postextubation) care, 
making it impossible to generalise their findings to contem-
porary practice.14–16
FIRST- line support for assistance in breathing in children 
(FIRST- ABC), therefore, addresses an important clinical 
dilemma faced daily by critical care clinicians: in a child 
requiring NRS, which modality, HFNC or CPAP, should 
they use as first- line therapy to achieve the best patient 
outcomes? Our research question was prioritised by clini-
cians as well as parents/patients. We previously successfully 
completed a pilot RCT, which supported the feasibility of 
performing a large pragmatic RCT comparing CPAP and 
HFNC in critically ill children, and informed its design and 
conduct.17 This protocol has been written in accordance 
with the Standard Protocol Items: Recommendations for 
Interventional Trials statement.18
METHODS
Hypothesis
In critically ill children assessed by the treating clinician 
to require NRS, first- line use of HFNC is non- inferior to 
CPAP in time to liberation from respiratory support.
Aim
To evaluate the clinical and cost- effectiveness of the use 
of HFNC, as compared with CPAP, when used as the first- 
line mode in critically ill children requiring NRS:
1. For an acute illness (step- up RCT).
2. Within 72 hours of extubation following a period of in-
vasive ventilation (step- down RCT).
Primary objective
To evaluate the non- inferiority of HFNC, as compared 
with CPAP, when used as the first- line mode of NRS, both 
as a step- up treatment (step- up RCT) and as a step- down 
treatment (step- down RCT), on the time to liberation 
from respiratory support.
Design
FIRST- ABC is a master protocol comprising two prag-
matic, multicentre, parallel groups, non- inferiority RCTs 
(step- up RCT and step- down RCT) with shared infra-
structure, including an internal pilot stage and inte-
grated health economic evaluation. This design allows 
the research question to be addressed in each of the 
two important populations in an efficient way by mini-
mising time and infrastructure costs as compared with 
conducting two sequential RCTs.19 The pragmatic study 
design ensures that research findings can be more easily 
generalised to real- world practice.
A non- inferiority design was chosen based on previous 
RCTs in this area and feedback from clinicians from 
the UK Paediatric Intensive Care Society—Study Group 
in July 2017 which indicated that the potential benefits 
of HFNC (in terms of patient comfort and ease of use) 
would mean that it would likely be preferred in usual 
practice even if not shown to be superior to CPAP.
Setting
FIRST- ABC is set in National Health Service (NHS) paedi-
atric critical care units (PICU and/or high- dependency 
units (HDUs)) across England, Wales and Scotland. 
General medical- surgical, cardiac and mixed units were 
considered for participation. Sites are eligible to take part 
if they confirm collective equipoise regarding the choice 
of first- line NRS in their unit and commit to following trial 
procedures, including randomisation and data collection. 
Sites can start recruitment only after a site initiation visit 
and all relevant regulatory approvals.
Population
Critically ill children assessed by the treating clinician to 
require NRS for (A) an acute illness (step- up RCT) or 
(B) within 72 hours of extubation following a period of 
invasive ventilation (step- down RCT).
Screening
Potentially eligible patients admitted/accepted for 
admission to the participating critical care unit will be 
screened against the inclusion/exclusion criteria by the 
local clinical/research team. For the step- up RCT, all 
admissions to the unit will be screened. For the step- down 
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RCT, all patients extubated during unit admission will be 
screened. From these, Screening and Enrolment Logs 
will record enrolled patients, reasons for exclusion and 
reasons eligible patients are not enrolled.
Inclusion criteria
1. Admitted/accepted for admission to PICU/HDU.
2. Age>36 weeks corrected gestational age and <16 years.
3. Assessed by the treating clinician to require NRS.
1. For an acute illness (step- up RCT).
2. Within 72 hours of extubation following a period of 
invasive ventilation (step- down RCT).
Exclusion criteria
1. Assessed by the treating clinician to require immediate 
intubation and invasive ventilation due to severe hy-
poxia, acidosis and/or respiratory distress, upper air-
way obstruction, inability to manage airway secretions 
or recurrent apnoeas.
2. Tracheostomy in place.
3. Received HFNC/CPAP for >2 hours in the prior 
24 hours.
4. On home non- invasive ventilation prior to PICU/HDU 
admission.
5. Presence of untreated air- leak (pneumothorax/pneu-
momediastinum).
6. Midfacial/craniofacial anomalies (unrepaired cleft 
palate, choanal atresia) or recent craniofacial surgery.
7. Agreed ‘not for intubation’ or other limitation of criti-
cal care treatment plan in place.
8. Previously recruited to FIRST- ABC (step- up RCT or 
step- down RCT on this or a previous admission).
9. Clinician decision to start other form of NRS (ie, not 
HFNC or CPAP, eg, bilevel positive pressure and nega-
tive pressure ventilation).
Randomisation
Randomisation will be performed after confirming 
eligibility and as close as possible to the anticipated 
start of the randomised treatment. In each RCT, eligible 
patients will be randomised in a 1:1 ratio to either CPAP 
or HFNC using a central telephone/web- based rando-
misation service available 24 hours/7 days a week. The 
randomisation sequence will be computer generated 
and variable block sizes will be used to strengthen allo-
cation concealment. Randomisation will be stratified by 
site and age (<12 months vs ≥12 months) to minimise 
imbalance arising from unit practices and interface 
selection.
The randomised treatment will be commenced as soon 
as practically possible. Following randomisation, each 
participant will be assigned a unique FIRST- ABC trial 
number and a case report form (CRF) completed by the 
local research team.
Delivery of HFNC
Any approved medical device capable of delivering 
heated, humidified, high flow through nasal cannulae 
can be used to provide HFNC at the prescribed gas flow 
rates during the trial period. To standardise treatment, 
clinical criteria and guidance for the initiation, mainte-
nance and weaning of HFNC are provided in a trial algo-
rithm (figure 1). The trial algorithms were developed 
iteratively in consultation with paediatric critical care 
clinicians across the UK (both via email and in person 
at a Collaborators’ Meeting held prior to the start of the 
trial).
The trial recommends that patients are assessed for 
response to the treatment, readiness to wean and for stop-
ping HFNC, as per the HFNC algorithm, at least twice per 
day (eg, at ward rounds).
Delivery of CPAP
CPAP will be started using an approved medical device 
at a set expiratory pressure of 7–8 cm H2O. The trial does 
not specify any particular device or patient interface for 
the provision of CPAP. To standardise treatment, clinical 
criteria and guidance for the initiation, maintenance 
and weaning of CPAP are provided in a trial algorithm 
(figure 2). It is recommended that patients are assessed 
for response to the treatment, readiness to wean and for 
stopping CPAP, as per the CPAP algorithm, at least twice 
per day (eg, at ward rounds).
 Clinical practice during the trial
Since staff in participating sites already use HFNC and 
CPAP, no additional central training related to the use of 
HFNC or CPAP will be provided for the trial, but resources 
for training in the trial algorithms will be provided. As 
the medical devices and interfaces that deliver HFNC and 
CPAP are easily distinguishable from each other, it will 
not be possible to blind the patient, parents/guardians 
or clinical staff.
The trial algorithms will be followed until the patient 
has been liberated from all forms of respiratory support 
for at least 48 continuous hours. As per current practice, 
clinicians will be able to stop HFNC/CPAP and switch to 
the other treatment or escalate to other forms of respi-
ratory support, if clinically deemed necessary. Prespec-
ified objective criteria to identify non- responders to 
HFNC/CPAP are provided in the algorithms as a guide 
for clinicians considering switching or escalating respira-
tory support. Reasons for switches or escalations will be 
recorded. Patients who switch or escalate treatments will 
remain in the trial and continue to be monitored until 
liberation from respiratory support. All other usual care 
(eg, sedation, feeding) will be at the discretion of the 
treating clinical team.
Consent procedures
Consent will be sought for the child (patient) from their 
parent/legal guardian. Children become eligible for 
FIRST- ABC when critically ill, a profoundly stressful time 
for parents/guardians, during which there are ethical 
concerns both about the burden of trying to understand 
the trial and the ability to provide informed consent. 
Initiation of NRS typically occurs during a time- sensitive 
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situation, where delays could be detrimental to the child 
and to the trial’s scientific validity. Moreover, both CPAP 
and HFNC are already widely used in standard practice 
across the NHS. Considering these reasons, FIRST- ABC 
has been given ethical approval to use a deferred consent 
model (‘research without prior consent’). Once a patient 
is confirmed eligible, they will be randomised and the 
allocated treatment (CPAP or HFNC) commenced as 
Figure 1 Algorithm for delivery of HFNC. *Titrate FiO2 while on HFNC to maintain peripheral oxygen saturations (SpO2) ⩾92% 
(or patient- specific target). †Respiratory distress defined as: mild (one accessory muscle used, mild indrawing of subcostal and 
intercostal muscles, mild tachypnoea, no grunting), moderate (two accessory muscles used, moderate indrawing of subcostal 
and intercostal muscles, moderate tachypnoea, occasional grunting); or severe (use of all accessory muscles, severe indrawing 
of subcostal and intercostal muscles, severe tachypnoea, regular grunting). CPAP, continuous positive airway pressure; FIRST- 
ABC, FIRST- line support for assistance in breathing in children; FiO2, fractional inspired oxygen; HFNC, high- flow nasal cannula.
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soon as possible. This model, developed in line with the 
CONseNt methods in paediatric Emergency and urgent 
Care Trials guidance,20 has been found acceptable to 
parents/guardians and clinicians in several recent RCTs 
in the PICU setting17 21–25 and is informed by experience/
feedback from the pilot RCT.17
Following randomisation, a trained, delegated member 
of the local research team will approach the child’s 
parents/guardians as soon as appropriate and practically 
possible to discuss the trial (usually within 24–48 hours 
of randomisation). A participant information sheet will 
be provided, covering information about the purpose 
of the trial; the consequences of participating or not; 
Figure 2 Algorithm for delivery of continuous positive airway pressure (CPAP). *Titrate FiO2 while on HFNC to maintain 
SpO2 ⩾92% (or patient- specific target). †Respiratory distress defined as: mild (one accessory muscle used, mild indrawing of 
subcostal and intercostal muscles, mild tachypnoea, no grunting), moderate (two accessory muscles used, moderate indrawing 
of subcostal and intercostal muscles, moderate tachypnoea, occasional grunting); or severe (use of all accessory muscles, 
severe indrawing of subcostal and intercostal muscles, severe tachypnoea, regular grunting). FAST- ABC, FIRST- line support for 
assistance in breathing in children; FiO2, fractional inspired oxygen; HFNC, high- flow nasal cannula.
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confidentiality; use of personal data; data security and the 
future availability of the trial results. A consent form (see 
online supplementary file 1) will be provided, indicating 
that: the information given has been read and under-
stood; participation is voluntary and consent can be with-
drawn at any time without consequence; and that consent 
is given for access to medical records to continue data 
collection, to receive a follow- up questionnaire and for 
anonymised data to be shared in the future. Due to age 
and severity of illness, it will not be possible to involve 
the patient in the consenting process. Instead, assent will 
be obtained prior to hospital discharge if their condition 
allows (eg, they regain mental capacity).
A modification of the consent procedure will be utilised 
for two rare situations where either the patient: (1) is 
discharged from hospital prior to obtaining consent or 
(2) dies prior to consent being sought.24 26 In the former, 
the local research team will follow up with the parent/
guardian, initially by phone and then by post, for consent. 
Postal contact will be made again if there is no response 
after 4 weeks. If no consent form is received within 4 weeks 
of the second letter, the participant will be included in the 
trial unless they notify the research team otherwise. In the 
latter situation, the local research team will obtain infor-
mation from colleagues and bereavement counsellors to 
establish the most appropriate clinical/research team 
member to notify the parents/guardians of involvement 
in the trial. If approach for consent is deemed not appro-
priate prior to the parent/guardian’s departure from 
hospital, then they will be approached by post 4 weeks 
postrandomisation. The letter will explain how to opt out 
of the trial. Postal contact will be made again if there is 
no response after 4 weeks. If no consent form is received 
within 4 weeks of the second letter, the participant’s data 
will be included in the trial.
If informed consent is refused or withdrawn, this deci-
sion will be respected and abided by, and no further 
contact made. All data occurring up to the point of this 
decision will be retained in the trial, unless parents/
guardians request otherwise.
Safety monitoring
Adverse event (AE) reporting will follow the Health 
Research Authority (HRA) guidelines on safety reporting 
in studies which do not useClinical Trials of Investiga-
tional Medicinal Products. The following events have 
been prespecified as potential AEs that could be related 
to CPAP and/or HFNC and observed in participants from 
the date and time of randomisation until 48 hours of 
liberation from all forms of respiratory support:
1. Nasal trauma.
2. Facial/neck trauma.
3. Abdominal distension.
4. Pneumothorax.
5. Pneumomediastinum.
6. Subcutaneous emphysema.
7. Facial thermal injury.
8. Respiratory arrest.
9. Cardiac arrest.
10. Aspiration
Occurrences of the specified, expected AEs will be 
recorded for all randomised patients. Considering that 
eligible patients are critically ill and at increased risk of 
experiencing AEs, occurrences of non- specified, AEs will 
only be reported if considered to be related to either CPAP 
or HFNC (ie, ‘possibly’, ‘probably’ or ‘definitely’ related). 
Any event classified as ‘severe’ or ‘life- threatening’ in 
severity is considered a serious AE (SAE) and must be 
reported to Intensive Care National Audit and Research 
Centre (ICNARC) Clinical Trials Unit (CTU). If the SAE 
is evaluated by the trial management group (TMG) as 
a related and unexpected SAE, the ICNARC CTU will 
submit a report to the Research Ethics Committee (REC) 
within 15 calendar days.
Questionnaire follow-up
At 6 months, after assessing the child’s survival status, each 
consenting parent will be sent a questionnaire (via email 
or post) by the ICNARC CTU to assess health- related 
quality of life (HrQoL) and health service/resource use. 
Non- responders will be followed up by telephone 3 weeks 
later.
OUTCOME MEASURES
Primary outcome
Time to liberation from respiratory support, defined as 
the start of a 48- hour period during which the child was 
free of all forms of respiratory support.
The primary outcome definition of respiratory support 
does not include administration of supplementary 
oxygen alone. In addition, the primary outcome will to 
be monitored/recorded after discharge from critical 
care, as necessary. We chose time to liberation from 
respiratory support, instead of rate of (re)intubation, as 
the primary outcome for several reasons, including: (1) 
through our patient and public involvement (PPI) work, 
parents/families reported that even though intubation 
was clearly an undesirable outcome, the fact that the 
child needed a ‘breathing machine’ of any description 
would be more important for them, in terms of assessing 
the success or failure of the intervention. Normalisation 
of ‘breathing’ was an important outcome prioritised over 
intubation; (2) since the rate of intubation on average 
was around 20% in the pilot RCT, nearly 80% of patients 
may not fulfil the intubation outcome. In these patients, 
several non- invasive support modes may be used, which 
prolong the time the patient is on ‘breathing support’ 
with resource implications for critical care. Clinicians felt 
that it was important that the effect of the intervention 
was assessed on patients who did not need intubation as 
well as on those who did. (3) unpublished data from the 
pilot RCT showed that the length of respiratory support 
is longer in patients who need intubation compared with 
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those who do not. Therefore, the adverse impact of intu-
bation is likely reflected in longer duration of respiratory 
support.
Secondary outcomes
 ► Mortality at PICU/HDU discharge, day 60 and day 
180.
 ► Rate of (re) intubation at 48 hours.
 ► Duration of PICU/HDU and hospital stay.
 ► Patient comfort, during randomised treatment and 
during NRS (ie, HFNC and/or CPAP), assessed using 
the COMFORT- B score.27
 ► Proportion of patients in whom sedation is used 
during NRS.
 ► Parental stress, in hospital at/around the time of 
consent at 24–48 hours, measured using the Parental 
Stressor Scale: PICU.28
 ► HrQoL at 6 months using age- appropriate Paedi-
atric Quality of Life Inventory (PedsQL)29 and Child 
Health Utility (CHU- 9D) questionnaire.30
Cost-effectiveness analysis outcomes
 ► Total costs at 6 months.
 ► Quality- adjusted life- years (QALYs) at 6 months.
 ► Incremental net monetary benefit gained at a 
willingness- to- pay of £20 000 per QALY at 6 months 
associated with HFNC versus CPAP.31
Data collection
To maximise efficiency, FIRST- ABC collaborates with 
the Paediatric Intensive Care Audit Network (PICANet) 
to make best use of established PICU data collection 
infrastructure. Where possible, recruited patients will 
be consented for data linkage with routine sources (eg, 
national death registration data via NHS Digital or equiv-
alent). Additional trial- specific data collection items are 
limited to the minimum required to deliver trial objec-
tives (table 1).
All participant data will be entered onto the secure 
electronic CRF and undergo validation checks for 
completeness, accuracy and consistency. The site prin-
cipal investigator will oversee and be responsible for data 
collection, quality and recording.
STATISTICAL METHODS
Sample size
To achieve 90% power with a type I error rate of 2.5% 
(one sided) to exclude the pre- specified non- inferiority 
margin of HR=0.75 requires 508 events to be observed. 
Based on pilot RCT data,17 we anticipate 5% censoring 
due to death or transfer, leading to a required sample size 
of 268 patients per group in each of the two RCTs. To 
allow for withdrawal/refusal of consent, and for exclusion 
due to non- adherence in the per- protocol (PP) popula-
tion, we will recruit a total sample size of 600 patients in 
each RCT.
Internal pilot
Data will be analysed at the end of the internal pilot stage 
(months 7–12 of the grant timeline) on patients recruited 
during the first 6 months in each RCT. The RCTs will 
progress from pilot to full trial based on prespecified 
progression criteria related to successful site set- up, 
screening and recruitment, and adherence. The final 
decision on progression will be made by the funder after 
Table 1 Patient data collection schedule
Baseline
At 
time of 
consent
During non- invasive 
respiratory support
End of PICU/
HDU stay
End of hospital 
stay
At 
6 months
In- hospital
  Clinical/baseline data ✔           
  Patient/parent details   ✔         
  Types of respiratory support 
received*
✔   ✔       
  Patient comfort and sedation 
use
    ✔       
  Parental stress   ✔         
  Discharge data       ✔ ✔   
  Safety monitoring data     ✔       
At follow- up
  PedsQL           ✔
  CHU- 9D           ✔
  Health services/resource use           ✔
*Including weaning, switches and escalations from high flow nasal cannula/continuous positive airway pressure.
CHU- 9D, Child Health Utility- 9D; HDU, high- dependency unit; PedsQL, Paediatric Quality of Life Inventory; PICU, paediatric intensive 
care unit.
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recommendation, or not, by the trial steering committee 
(TSC).
Clinical effectiveness analysis
All analyses will be publicly lodged32 in a statistical anal-
ysis plan, a priori, before the investigators are unblinded 
to any trial outcomes. Following best practice for non- 
inferiority trials, the primary analyses will be undertaken 
in both intention- to- treat (ITT) and PP populations, 
with robust conclusions possible in the situation where 
both populations provide concordant results. Results will 
be reported in accordance with the Consolidated Stan-
dards of Reporting Trials statement extensions for non- 
inferiority and pragmatic trials.33 34
Analyses will be undertaken independently for each 
RCT. In each RCT, baseline patient characteristics will 
be compared between the two groups to observe balance 
and the success of randomisation. These comparisons will 
not be subjected to statistical testing. The delivery of the 
intervention will be described for each group in detail, 
including (but not limited to) number and percentage 
of patients who commence the randomised treatment, 
remain on the randomised treatment until liberation 
from ventilation, who are changed to a different mode of 
respiratory support.
HFNC will be considered non- inferior to CPAP if 
the lower bounds of the 95% CIs for the HR from Cox 
regression models on time to liberation from respira-
tory support fitted in both the ITT and PP populations 
exclude the prespecified non- inferiority margin of 0.75 
(corresponding to approximately a 16- hour increase in 
median time to liberation, based on pilot RCT data). 
This margin was considered adequate such that the 
other potential benefits of HFNC in terms of comfort 
and tolerability would mean that it would be likely to be 
preferred in usual practice. The Cox regression models 
will be adjusted for important baseline characteristics. 
The covariates for inclusion in the regression models will 
be selected a priori based on an established relationship 
with outcome for critically ill children, and not because of 
observed imbalance, significance in univariable analyses 
or by a stepwise selection method.
Subgroup analyses for the primary outcome will be 
performed to test for interactions between the effect of 
allocated treatment group and the following baseline 
covariates:
 ► Age (<12 months vs ≥12 months).
 ► Severity of respiratory distress at randomisation 
(severe vs mild/moderate).
 ► Comorbidities (none vs neurological/neuromuscular 
vs other).
 ► Sp02/fractional inspired oxygen (SF) ratio at 
randomisation.
 ► For step- up RCT only:
 – Clinical indication (bronchiolitis vs other respira-
tory (airway problem, asthma/wheeze or any other 
respiratory) versus cardiac versus other (neurolog-
ical, sepsis/infection, any other)).
 – Whether child was on NRS at randomisation (yes/
no).
 ► For step- down RCT only:
 – Length of prior invasive mechanical ventilation (<5 
days vs ≥5 days).
 – Reason for invasive mechanical ventilation (cardi-
ac vs other).
 – Planned (randomisation followed by extubation) 
versus rescue (extubation followed by randomisa-
tion) NRS.
We will treat age as a continuous variable and deter-
mine whether the model goodness- of- fit is better versus 
treating age as a categorical term for any analyses focusing 
on those over the age of 12 months. We anticipate a high 
proportion of patients will be aged <12 months, and 
therefore, exploration of age effects in the older ages will 
only be conducted if there are sufficient patient numbers.
As a sensitivity analysis, the primary analysis will be 
repeated using time to start weaning of NRS (ie, duration 
of ‘acute’ respiratory support) and time to meeting objec-
tive ‘readiness to wean NRS’ criteria.
Secondary analyses of binary outcomes (mortality, 
reintubation) will be performed by Fisher’s exact test 
and adjusted logistic regression. Duration of survival to 
day 180 will be plotted as Kaplan- Meier survival curves, 
compared unadjusted with the log rank test and adjusted 
using Cox regression models. Analyses of duration of 
PICU/HDU and hospital stay will be performed by 
Wilcoxon rank- sum tests, stratified by survival status. Anal-
yses of COMFORT- B score, sedation use, PSS:PICU and 
HrQoL will be performed by t- tests and adjusted linear 
regression.
In the step- up RCT, a single interim analysis will be 
carried out after the recruitment and follow- up to day 
60 of 300 patients. The interim analysis will use a Peto- 
Haybittle stopping rule to recommend early termina-
tion due to superiority of either intervention (p<0.001) 
in time to liberation from respiratory support or 
evidence of harm from either intervention (p<0.05) in 
mortality at day 60. Both tests will be performed using a 
log- rank test on all available data within the ITT popula-
tion. Further interim analyses will be performed only if 
requested by the data monitoring and ethics committee 
(DMEC).
In the step- down RCT, due to faster than antici-
pated recruitment, no formal interim analysis will be 
performed. Safety data (counts and percentages of AEs 
by arm and a line listing of SAEs) will be available for 
scrutiny by the DMEC, by the end of the internal pilot 
stage.
Integrated health economic evaluation
The cost- effectiveness analysis (CEA) will take an NHS 
and Personal Social Services perspective.31 Patient- level 
resource use data will be obtained from CRFs, PICANet 
and a parent- completed Health Services Questionnaire 
(HSQ). Resource use data from the PICU/HDU stay 
will be taken from the CRF and linked routine data 
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from PICANet. Information on subsequent PICU/
HDU and hospital admissions will be obtained via data 
linkage with PICANet and NHS Digital and also through 
completion of the HSQ. Data on the level of care for 
PICU bed- days will be gathered through routine collec-
tion of the Paediatric Critical Care Minimum Dataset 
in the participating sites via the PICANet database. Use 
of primary care and community health services will be 
assessed by HSQ at 6 months. Patient- level resource 
use data will be combined with appropriate unit costs 
from the NHS payment by results and Personal Social 
Services Research Unit databases to report total costs 
per patient for up to 6 months postrandomisation. Data 
from PedsQL and CHU- 9D at 6 months will be combined 
with survival data to report QALYs at 6 months. The 
CEA will follow the ITT principle and report the mean 
(95% CI) incremental costs, QALYs and net monetary 
benefit at 6 months. The CEA will use multilevel linear 
regression models that allow for clustering of patients at 
site. The analysis will adjust for key baseline covariates 
at both patient and site level.
ETHICS AND DISSEMINATION
Research ethics
The trial received favourable ethical opinion from NHS 
East of England—Cambridge South Research Ethics 
Committee (reference number: 19/EE/0185) and 
approval from the HRA (Integrated Research Applica-
tion System (IRAS) number: 260536). Evidence of local 
confirmation of capacity and capability at each site must 
be provided to the ICNARC CTU prior to site activation.
Confidentiality
ICNARC CTU will act to preserve participant confidenti-
ality and will not disclose or reproduce any information 
by which participants could be identified. All data will be 
stored securely.
Oversight
The TMG, led by the chief investigator, is responsible 
for the management of FIRST- ABC. It meets regularly 
and includes the Investigators and ICNARC CTU trial 
team. FIRST- ABC is managed by the ICNARC CTU in 
accordance with the Medical Research Council’s Good 
Research Practice: Principles and Guidelines35 which 
is based on the International Conference on Harmoni-
sation guidelines on Good Clinical Practice36 principles 
and the UK Department of Health’s Policy Framework 
for Health and Social Care Research.37 The on- site moni-
toring plan will follow a risk- based strategy.
A majority independent TSC has been established to 
monitor trial progress and includes PPI representatives, 
experienced clinicians and researchers/statisticians, in 
addition to the chief investigator and head of research 
at ICNARC. An independent DMEC, comprising experi-
enced clinicians and statisticians, has been established to 
monitor patient recruitment and retention, adherence 
and safety.
The Great Ormond Street Hospital for Children NHS 
Foundation Trust is the trial sponsor (reference: 17IA05). 
As the sponsor is an NHS organisation, NHS indem-
nity will apply for legal liability arising from the design, 
management and conduct of the research.
Patient and public involvement
We had considerable PPI input into the pilot RCT17 as 
well as the main trial described here. Following the pilot 
RCT, the PPI Group for Research at Great Ormond Street 
Hospital was consulted on the choice of the primary 
outcome for the main RCTs (see Outcome measures 
section). The parent of a child who received respiratory 
support is a coinvestigator and has actively contributed 
to the trial design and procedures, including the use of 
deferred consent and patient/parent information sheets 
and other materials.
Trial status
This paper presents the master protocol (V.1.2, dated 23 
January 2020)38 for the two largest RCTs studying the clin-
ical and cost effectiveness of HFNC therapy as the first- 
line mode of NRS in critically ill children. It will provide 
robust evidence for the two distinct but common clinical 
scenarios in which NRS is primarily used. The first partic-
ipant was recruited in August 2019. At the time of submis-
sion, patient recruitment was ongoing—with recruitment 
planned to complete in November 2020 and January 2022 
for the step- down RCT and step- up RCT, respectively. 
Each RCT will be disseminated independently, including 
through publication in peer- reviewed medical journals 
and at national and international conferences.
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